|Articles|August 30, 2021
Dermavant Moves One Step Closer to Potential New Treatment Option for Patients with Plaque Psoriasis
Author(s)Dermavant
Advertisement
Partner Perspectives
Dermavant Sciences recently announced that the FDA accepted for filing a New Drug Application (NDA) for tapinarof for the treatment of plaque psoriasis in adult patients. Tapinarof is an investigational novel, therapeutic aryl hydrocarbon receptor modulating agent, in development as a once-daily, steroid-free and cosmetically elegant topical cream for the treatment of plaque psoriasis and atopic dermatitis. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.
Message from Dermavant CEO, Todd Zavodnick
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
The Weekly Roundup: December 1-5
3
Nearly Half of Female Psoriasis Patients Report IPV, Study Finds
4
Experts See Promise in AI for Atopic Dermatitis Care
5
